US Stocks Movement | Novo Nordisk Pre-market Down 10% CagriSema Trial Less Effective Than Eli Lilly's Zepbound

Gelonghui, February 23 — After the release of CagriSema data, Novo Nordisk’s stock plummeted in pre-market trading, dropping as much as 10.4% to $42.49. On the news, Novo Nordisk announced clinical data for CagriSema, showing a 23% weight loss in the REDEFINE 4 trial, but the study did not meet its primary endpoint. In the clinical trial, the company’s CagriSema did not achieve non-inferiority to Eli Lilly’s Tirzepatide in terms of efficacy.